In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Miragen Therapeutics, Inc.

http://www.miragen.com/

Latest From Miragen Therapeutics, Inc.

New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure

Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.

Cardiovascular Clinical Trials

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

Deals Intellectual Property

Pipeline Watch: Phase III Starts With QPI-1002, Enfortumab Vedotin And ZYN-002

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger

Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.

Cancer Inflammation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Other Names / Subsidiaries
    • Myeloma Health LLC
    • Signal Genetics LLC
    • Signal Genetics, Inc.
UsernamePublicRestriction

Register